Significant progress in lung cancer research has introduced novel treatments, such as epidermal growth factor receptor (EGFR)-targeted therapies, which are advised as the primary treatment for NSCLC with EGFR mutations, with these mutations predominantly manifesting in ADC. This evidence concerns the gene EGFR and lung carcinoma.